AION Receives FDA Clearance for Its iTempShield Skin-Wearable Device and Software Platform for Professional and Retail Environments
AION Biosystems will primarily focus on early infection detection in cancer patients and long-term care residents.
- AION Biosystems will primarily focus on early infection detection in cancer patients and long-term care residents.
- Unlike any other skin-applied wearable, the low-profile iTempShield adheres to the surface of the skin of the chest.
- AION architected the platform to easily integrate into hospital or physician medical records systems and remote patient monitoring systems.
- Healthcare providers interested in learning more about the remote monitoring device and platform can contact [email protected] or visit the company’s website for more information.